In silico studies on CBD tau fibrils predicted that, theoretically, among six potential binding sites, only two sites would be favourable for PI2620 (one entry site and one surface site) [31], while in AD tau fibrils where 12 binding sites would be available, PI2620 would preferentially bind to the core site and the entry site [28]. Here, MAPT is linked to Alzheimer disease.